Array BioPharma Set To Raise Funds By Partnering Discovery Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
Early partnering of preclinical glucokinase activator program would allow Array to stay focused on oncology and inflammation.
You may also be interested in...
Array Biopharma Wins Two Important Deals In Six Months, But Wall Street Shrugs
To management's frustration, the biotech's deals with Novartis and Amgen haven't helped its market cap, one more sign that validating deals with Big Pharma don't move investors.
Array Biopharma Wins Two Important Deals In Six Months, But Wall Street Shrugs
To management's frustration, the biotech's deals with Novartis and Amgen haven't helped its market cap, one more sign that validating deals with Big Pharma don't move investors.
Amgen Pays Array $60 Million Upfront For Its Phase One Type 2 Diabetes Compound
The deal for ARRY-403 includes up to $666 million in milestones, a two-year research-funding agreement and U.S. co-promotion option.